ClinConnect ClinConnect Logo
Search / Trial NCT06886971

Strategies to AchieVe Viral Suppression for Youth With HIV

Launched by JOHNS HOPKINS UNIVERSITY · Mar 14, 2025

Trial Information

Current as of April 30, 2025

Recruiting

Keywords

Adolescents Long Acting Antiretroviral Treatment Youth Young Adu;Ts Viral Suppression Effectiveness

ClinConnect Summary

The SAVVY Study is looking to improve the health of young people living with HIV by exploring better ways to help them manage their treatment. Even though there are effective treatments available, many adolescents and young adults struggle to keep their HIV under control, which can lead to serious health risks. This trial aims to give participants more choices for their HIV medications, including options for long-acting injections that don't require daily pills. The study will also help participants overcome any obstacles they face in accessing these treatments and will gather important information to improve care for young people with HIV.

To be eligible for the study, participants need to be between 12 and 24 years old, currently taking HIV medication, and willing to communicate with their healthcare provider about their treatment. However, individuals with certain health issues, specific medication interactions, or severe mental health challenges may not qualify. Those who join can expect support in finding the best treatment option for them and guidance throughout the process. This study is an important step in helping young people achieve better health outcomes and ultimately reducing the impact of HIV in their lives.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • prescribed ART,
  • willing to sign informed consent (including communication with one's primary HIV provider)
  • Exclusion Criteria:
  • Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV)
  • disallowed medications,
  • pregnancy.
  • Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation;
  • severe illness/hospitalization at the time of enrollment,
  • plan to move away in the next 12 months.

About Johns Hopkins University

Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.

Locations

Baltimore, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Allison Agwu, MD, SCM

Principal Investigator

Johns Hopkins University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported